Amphista Therapeutics Limited, a Cambridge, United Kingdom-based biotechnology company developing targeted protein degradation medicines, has administered the first patient dose of AMX-883 in the Phase 1 BRAMLIE trial for relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Announced on October 12, 2026, the milestone marks the company’s first clinical-stage programme and follows United States Food and Drug Administration clearance of its investigational new drug application in June.
The study, registered as NCT07723703, is expected to enrol approximately 54 patients and will initially investigate the safety, tolerability, pharmacokinetics and preliminary antileukemic activity of orally administered AMX-883. The investigational compound is designed to degrade BRD9, a protein involved in chromatin remodelling and the regulation of myeloid cell differentiation, through recruitment of the DCAF16 E3 ubiquitin ligase.
The development introduces a distinct experimental approach to a disease increasingly treated through molecularly selected therapies. While several newer AML medicines act against genetic or molecular abnormalities found in particular patient populations, Amphista is developing AMX-883 around a biological mechanism that it believes could operate across different leukemia subtypes. The company reported preclinical activity independent of cytogenetic status, allowing BRAMLIE to enrol eligible patients without requiring a specific AML mutation.
The central question is whether these laboratory findings will translate into a reproducible therapeutic response in humans. First-patient dosing establishes that clinical investigation has begun, but no human response rates, remission outcomes or treatment-related safety findings have been reported for AMX-883. The initial trial will therefore determine whether the drug can achieve suitable exposure and an acceptable safety profile while providing early evidence that BRD9 degradation has meaningful effects in patients with advanced myeloid malignancies.
How will the 54-patient BRAMLIE Phase 1 trial evaluate AMX-883 safety and early antileukemic activity?
BRAMLIE is an open-label, multicentre, non-randomised Phase 1 study designed to establish the initial human safety and pharmacological profile of AMX-883. Its first module includes oral monotherapy dose-escalation cohorts, a food-effect assessment and a separate component examining administration alongside posaconazole. The study is primarily focused on dose-limiting toxicities, treatment-emergent adverse events and identifying an appropriate dose for further investigation.
Participants must have relapsed or refractory AML after available standard therapies or qualifying high-risk MDS, with eligibility also requiring adequate organ function and an Eastern Cooperative Oncology Group performance status of 0 to 2. The study excludes certain conditions that could complicate interpretation or increase treatment risks, including active central nervous system leukemia, clinically significant cardiovascular disease and uncontrolled infections. These requirements define a medically selected early-phase population rather than every patient who might eventually qualify for treatment.
The trial will also examine how AMX-883 behaves after oral administration, including maximum and minimum plasma concentrations, drug exposure over time, elimination characteristics and the influence of food. Pharmacokinetic assessments are important because an orally administered degrader must achieve adequate systemic exposure while maintaining an acceptable safety profile. For AMX-883, demonstrating predictable exposure will help researchers identify doses suitable for evaluating the intended biological mechanism.
Preliminary efficacy endpoints include composite complete remission, overall response, duration of remission, transfusion independence and survival-related measures. For patients with high-risk MDS, the protocol includes disease-specific response and hematologic improvement assessments. These outcomes may identify early antitumour activity, but BRAMLIE is not powered or designed to establish a definitive survival advantage against an existing treatment.
The registry lists an estimated primary completion date of December 4, 2028, with final study completion expected later. These are planning estimates rather than confirmed dates for the disclosure of clinical results. Initial dose-escalation findings could inform subsequent development decisions, although Amphista has not announced a specific date for presenting its first human safety or efficacy dataset.
Why is AMX-883 targeting BRD9 rather than a specific acute myeloid leukemia mutation?
AML arises through the abnormal proliferation of immature myeloid cells that fail to complete their normal differentiation into functioning blood cells. The disease encompasses numerous genetic and biological subtypes, and differences in molecular characteristics can strongly influence prognosis and treatment selection. Modern targeted therapies have improved outcomes for certain populations, but many patients either lack the relevant actionable alteration or develop resistance following treatment.
BRD9 is a component of the non-canonical BAF chromatin-remodelling complex, which participates in controlling DNA accessibility and gene expression. Amphista’s therapeutic rationale is that BRD9 helps maintain the differentiation blockade associated with AML, allowing malignant cells to persist in an immature state. Removing BRD9 could potentially alter the gene-regulatory processes supporting leukemic cell survival and encourage differentiation.
This approach differs from therapies designed around specific oncogenic mutations. For example, approved FLT3 inhibitors are used in selected patients with qualifying FLT3 alterations, while IDH inhibitors target disease involving relevant IDH mutations. Menin inhibitors have also introduced new treatment options for particular molecularly defined forms of relapsed or refractory AML.
Amphista reported that AMX-883 demonstrated differentiation-promoting activity across diverse AML models irrespective of their underlying cytogenetic characteristics. The company also described activity in patient-derived tumour models and inhibition of tumour growth in preclinical investigations. Those findings support the decision to enrol patients without requiring a particular mutation, but they do not establish that the medicine will work equally well across all AML subtypes.
The broader clinical opportunity depends on demonstrating that BRD9 represents a sufficiently important biological dependency in human leukemia. Even if the target is present across numerous disease subtypes, differences in tumour biology could affect sensitivity to degradation. The absence of a mutation-based enrolment restriction should therefore be interpreted as an exploratory clinical strategy rather than proof of universal responsiveness.
How does the DCAF16 targeted protein degradation mechanism differ from conventional cancer drugs?
Targeted protein degradation represents an approach to drug discovery in which a compound promotes the destruction of a selected protein rather than simply blocking its activity. Many established targeted medicines act by binding to an enzyme or receptor and inhibiting a particular function. Protein degraders instead recruit components of the cell’s natural protein-disposal machinery, potentially allowing the removal of proteins that are difficult to inhibit through conventional pharmacology.
AMX-883 uses Amphista’s proprietary Targeted Glue approach to recruit DCAF16, an E3 ubiquitin ligase component, to BRD9. This interaction is intended to mark BRD9 for destruction by the cell’s proteasomal machinery. The company describes the resulting mechanism as rapid and selective, with preclinical experiments demonstrating extensive degradation of the target protein.
The DCAF16 mechanism is differentiated from established degrader approaches that commonly recruit the E3 ligase systems associated with cereblon or von Hippel-Lindau protein. Expanding the range of ligases available for drug development could create opportunities to address targets that are difficult to degrade through existing molecular architectures. However, improved target degradation in laboratory studies does not necessarily mean improved therapeutic efficacy or safety in patients.
Scientific research published in Nature Communications in October 2025 provides supporting mechanistic evidence for Amphista’s platform. The investigators described AMPTX-1, an experimental BRD9-targeted degrader that recruits DCAF16 through a reversible covalent interaction involving a specific cysteine residue. Laboratory and animal studies demonstrated selective BRD9 degradation and supported the feasibility of using this ligase-recruitment strategy.
AMPTX-1 should not be confused with AMX-883, the clinical candidate now being investigated in BRAMLIE. The published research establishes proof of concept for the underlying chemical and biological approach, but it does not provide human efficacy or safety evidence for AMX-883. The clinical trial will need to establish whether the investigational medicine produces adequate BRD9 degradation in patients at doses that can be tolerated.
Can AMX-883 eventually address resistance to venetoclax-based leukemia treatment?
One of the most commercially and clinically relevant aspects of Amphista’s programme is its potential relationship with venetoclax-based treatment. Venetoclax, a BCL-2 inhibitor, is commonly used with hypomethylating agents such as azacitidine in patients with newly diagnosed AML who are unsuitable for intensive chemotherapy. Although this approach has expanded treatment options, resistance and disease recurrence remain important limitations.
Amphista has reported preclinical evidence suggesting that BRD9 degradation may influence biological pathways associated with venetoclax resistance. In laboratory experiments, the company observed changes in markers linked to resistance and reported that AMX-883 prevented the emergence of resistance in long-term cell culture models. It also described synergistic antitumour activity when AMX-883 was combined with venetoclax in preclinical models.
These findings provide a rationale for examining combinations after the initial safety profile has been established. However, synergy observed in laboratory or animal models does not guarantee improved remission rates or longer survival in humans. Combination treatment may also produce additional toxicity, particularly in patients with compromised bone marrow function and extensive prior treatment exposure.
Amphista previously identified combinations with venetoclax and azacitidine as a potential future development direction. The company’s October announcement reiterates its intention to investigate AMX-883 alongside established treatments after obtaining sufficient monotherapy information, including possible use in earlier treatment settings. Such programmes remain prospective, and no clinical benefit from combining AMX-883 with venetoclax has been demonstrated.
The initial BRAMLIE protocol also includes a component involving posaconazole, but this should not be mistaken for the proposed antileukemic combination strategy. Posaconazole is an antifungal medication used in patients at risk of serious fungal infections, including certain individuals receiving intensive leukemia treatment. Its inclusion in the registered study supports investigation of drug exposure and interaction considerations rather than an established anticancer synergy.
Why will posaconazole interactions and hematologic safety require particular attention?
Patients with AML often receive multiple medicines alongside anticancer treatment, including antimicrobials, transfusion support and therapies addressing treatment complications. Drug interactions can therefore influence whether a promising experimental agent can be used safely within standard oncology practice. For an orally administered compound, understanding how accompanying medications affect systemic exposure is an important part of early development.
Posaconazole is a potent inhibitor of CYP3A-related drug metabolism and can increase exposure to certain medicines administered concurrently. BRAMLIE includes dose-escalation cohorts involving AMX-883 with posaconazole to examine the combination under controlled clinical conditions. The available protocol does not establish the magnitude or clinical significance of a possible interaction, making the results of this assessment important for future treatment planning.
Hematologic safety is another central concern because AML and high-risk MDS frequently involve severe impairment of normal blood-cell production. Patients may enter clinical trials with anemia, thrombocytopenia or neutropenia, creating challenges when distinguishing disease-related complications from drug-related toxicity. Early-phase investigators must therefore evaluate adverse events in the context of baseline disease severity and prior treatment exposure.
The BRAMLIE protocol includes monitoring for dose-limiting toxicities during the first 28-day treatment cycle, alongside broader adverse-event surveillance. It also records laboratory abnormalities and clinically relevant complications that may influence dose selection. These assessments will help establish whether increasing drug exposure produces unacceptable toxicity or whether a biologically active dose can be pursued.
Theoretical safety concerns associated with differentiation-promoting therapies also deserve consideration, although they should not be presented as observed AMX-883 adverse effects. Other leukemia medicines that induce cellular differentiation can produce clinically significant inflammatory complications, including differentiation syndrome. Whether AMX-883 presents comparable risks remains unknown and must be determined through clinical evidence rather than assumed from its proposed mechanism.
How does AMX-883 compare with the growing class of mutation-specific AML treatments?
The AML treatment landscape has changed substantially as genetic testing has become central to therapeutic decision-making. Mutation-directed agents can provide meaningful benefits in selected patient populations, but their use is determined by the molecular characteristics of the disease and the precise approved indication. Patients without a qualifying alteration may not be eligible for those medicines, while individuals whose disease develops resistance may require alternative strategies.
Menin inhibition provides a recent example of this evolution. The FDA approved revumenib for relapsed or refractory acute leukemia involving KMT2A translocations in November 2024 and subsequently expanded its use to qualifying NPM1-mutated AML in October 2025. Ziftomenib received FDA approval in November 2025 for adults with relapsed or refractory AML carrying a susceptible NPM1 mutation and lacking satisfactory alternative treatment options.
These approvals demonstrate that differentiation-related pathways can be exploited therapeutically in molecularly selected leukemia populations. However, AMX-883 targets a different biological mechanism, and its proposed use across genetically diverse AML populations remains a hypothesis. The early human study will be essential for determining whether this broader strategy produces a clinically useful response.
BRD9 degradation also differs from simply inhibiting the protein’s bromodomain function. Removing the full protein may affect biological interactions beyond those blocked by a conventional inhibitor, potentially changing the consequences for malignant cells. Whether that broader disruption produces greater antileukemic activity or introduces additional toxicity will depend on clinical pharmacology and patient outcomes.
Amphista is not the first organisation to investigate BRD9 degradation as a drug-discovery strategy. Earlier clinical-stage approaches have used different protein-degradation architectures, including programmes involving cereblon-based mechanisms. AMX-883 is differentiated by its DCAF16-recruiting approach and its focus on AML, but the available evidence does not support a conclusion that it is clinically superior to other degrader technologies.
How does entering clinical development strengthen Amphista Therapeutics’ biotechnology strategy?
AMX-883 is the first internally developed Amphista asset to enter human testing, creating a milestone for a company previously recognised primarily for its protein-degradation discovery platform and pharmaceutical research collaborations. The transition is important because a technology platform can demonstrate molecular activity and generate licensing opportunities without necessarily establishing that its compounds can be developed into clinically useful medicines.
The company’s earlier commercial relationships provide context for its development strategy. In May 2022, Amphista announced a research and licensing collaboration with Bristol Myers Squibb that included a $30 million upfront payment and potential performance-based milestones. The companies subsequently disclosed discovery milestones under the agreement, reflecting progress in partnered research programmes.
Amphista also established a collaboration with the healthcare business of Merck KGaA in Germany to discover protein degraders for oncology and immunology applications. That agreement included up to €39 million in combined upfront and research funding for three initial programmes, with additional payments dependent on development and commercial achievements. The larger potential milestone figures associated with these partnerships should not be treated as money already received.
These relationships demonstrate pharmaceutical industry interest in Amphista’s degrader technology, but they are separate from proof of efficacy for AMX-883. The start of BRAMLIE now creates a pathway for collecting human data on the company’s own clinical candidate. Positive results could inform additional internal development and partnering discussions, although the programme remains at its earliest clinical stage.
Amphista is privately held and does not have a publicly traded share price. The company has not disclosed a current cash balance, updated financing runway or a dedicated clinical development budget for AMX-883 in the October announcement. Its ability to progress through larger studies will depend on future data, funding requirements and development priorities.
What are the next milestones for the BRAMLIE trial and Amphista’s BRD9 programme?
The immediate priority is safe dose escalation and the collection of interpretable pharmacokinetic information from the first participants. Investigators will need to establish how AMX-883 exposure changes with increasing doses, whether adverse events limit escalation and whether the medicine demonstrates evidence of engagement with its intended biological target. The trial includes exploratory measurement of BRD9 expression in peripheral blood mononuclear cells, providing one potential pharmacodynamic assessment.
Biomarker results will be particularly important because a new protein degrader needs evidence that its proposed mechanism operates in humans. Demonstrating reduced BRD9 expression in an accessible cell population would provide evidence of biological activity, although it would not automatically establish equivalent target degradation in leukemic cells or a clinical response. Correlating exposure, target engagement and disease outcomes will be necessary for identifying a potentially useful dose.
Early remission findings could provide another development signal, particularly if responses occur across patients with differing genetic characteristics. However, a small, uncontrolled Phase 1 study cannot reliably establish whether the drug works across AML subtypes or produces better outcomes than available therapy. The durability of any response and the clinical circumstances of responding patients would be as important as the initial response rate.
The first patient dose also creates the foundation for the company’s planned combination-development strategy. If the monotherapy findings establish an acceptable safety profile and evidence of biological activity, Amphista may be able to investigate AMX-883 alongside established anticancer agents. Such progression will depend on the accumulating clinical evidence and the regulatory requirements applicable to subsequent study components.
For Amphista Therapeutics, BRAMLIE represents a test of two linked propositions: that DCAF16 can be exploited successfully for targeted protein degradation in humans, and that removing BRD9 can provide meaningful antileukemic activity in patients with difficult-to-treat myeloid malignancies. The company has established a mechanistic rationale through preclinical research and has now begun human investigation, but neither proposition has yet been clinically confirmed.
The decisive milestones will be evidence of tolerable systemic exposure, reproducible target degradation and credible antileukemic responses. Those results will determine whether AMX-883 can progress beyond an innovative laboratory mechanism towards a treatment candidate capable of addressing the persistent unmet need in relapsed or refractory AML and high-risk MDS.
